Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients

FTY720 is a new and effective immunosuppressive agent, which produces peripheral blood lymphopenia through a lymphocyte homing effect. We investigated the relationship between the dose of FTY720 or blood concentration (pharmacokinetics, PK) and peripheral lymphopenia (pharmacodynamics, PD) in 23 kid...

Full description

Bibliographic Details
Main Authors:	S.I. Park, C.R. Felipe, P.G. Machado, R. Garcia, A. Skerjanec, R. Schmouder, H. Tedesco-Silva Jr., J.O. Medina-Pestana
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica 2005-05-01
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	FTY720 Lymphopenia Pharmacokinetics Pharmacodynamics Immunosuppression Renal transplants
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000500005

Similar Items

Behavioral Analyses in Dark Agouti Rats Following Repeated Systemic Treatment With Fingolimod (FTY720)
by: Marie Jakobs, et al.
Published: (2024-11-01)

The protective role of FTY720 in promoting survival of allograft fat in mice
by: Yi Yi, et al.
Published: (2022-09-01)

Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis
by: Kathrin Bail, et al.
Published: (2017-07-01)

The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
by: Alessandra Gonçalves Commodaro, et al.
Published: (2012-07-01)

The functional antagonist of sphingosine-1-phosphate, FTY720, impairs gut barrier function
by: Sohini Sikdar, et al.
Published: (2024-08-01)

Effect of FTY720 on transfusion-related acute lung injury: a preliminary investigation
by: Yaling ZHOU, et al.
Published: (2023-05-01)

Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells
by: Yi Zhao, et al.
Published: (2018-07-01)

FTY720 in immuno-regenerative and wound healing technologies for muscle, epithelial and bone regeneration
by: Monica Behara, et al.
Published: (2023-05-01)

A genome-wide screen for FTY720-sensitive mutants reveals genes required for ROS homeostasis
by: Kanako Hagihara, et al.
Published: (2017-11-01)

FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis
by: Laurent Kremer, et al.
Published: (2019-03-01)

Anti-tumor drug FTY720 regulates p53-dependent transcription
by: YAO Han, XU Wen-bin, WANG Dong-lai
Published: (2021-03-01)

Synthesis of Novel FTY720 Analogs with Anticancer Activity through PP2A Activation
by: Jitendra Shrestha, et al.
Published: (2018-10-01)

FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury
by: Thomas V. Rousselle, et al.
Published: (2020-06-01)

FTY720 Reduces the Biomass of Biofilms in <i>Pseudomonas aeruginosa</i> in a Dose-Dependent Manner
by: Abdurahman A. Niazy, et al.
Published: (2024-07-01)

The Effects of the S1P Receptor Agonist Fingolimod (FTY720) on Central and Peripheral Myelin in Twitcher Mice
by: Sibylle Béchet, et al.
Published: (2024-03-01)

Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury
by: Raffaela Cipriani, et al.
Published: (2017-07-01)

FTY720 Exerts Anti-Glioma Effects by Regulating the Glioma Microenvironment Through Increased CXCR4 Internalization by Glioma-Associated Microglia
by: Xu-Dong Guo, et al.
Published: (2020-03-01)

Cardioprotective Effects of Sphingosine-1-Phosphate Receptor Immunomodulator FTY720 in a Clinically Relevant Model of Cardioplegic Arrest and Cardiopulmonary Bypass
by: Naseer Ahmed, et al.
Published: (2019-07-01)

Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade
by: Janet L. Martin, et al.
Published: (2017-08-01)

The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
by: Maryam Naseh, et al.
Published: (2021-06-01)

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A‐RIPK1‐dependent necroptosis
by: Sahar A. Saddoughi, et al.
Published: (2012-11-01)

Peripheral T Cell Depletion by FTY720 Exacerbates Hypoxic-Ischemic Brain Injury in Neonatal Mice
by: Josephine Herz, et al.
Published: (2018-08-01)

Presynaptic Release-Regulating Sphingosine 1-Phosphate 1/3 Receptors in Cortical Glutamatergic Terminals: Adaptations in EAE Mice and Impact of Therapeutic FTY720
by: Alessandra Roggeri, et al.
Published: (2023-09-01)

The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage
by: Stradner Martin H, et al.
Published: (2011-12-01)

FTY720 Inhibits the Development of Collagen-Induced Arthritis in Mice by Suppressing the Recruitment of CD4+ T Lymphocytes
by: Zhu C, et al.
Published: (2021-05-01)

Fingolimod (FTY720) improves postoperative cognitive dysfunction in mice subjected to D-galactose-induced aging
by: Jie Zhang, et al.
Published: (2020-01-01)

Therapeutic approach to mite-induced intractable dermatitis using novel immunomodulator FTY720 ointment (fingolimod) in NC/Nga mice
by: Takumi Tsuji, et al.
Published: (2016-04-01)

Sex-dependent efficacy of sphingosine-1-phosphate receptor agonist FTY720 in mitigating Huntington’s disease
by: Jingyun Wu, et al.
Published: (2025-01-01)

Injectable Hydrogel Loaded with CDs and FTY720 Combined with Neural Stem Cells for the Treatment of Spinal Cord Injury
by: Qi Z, et al.
Published: (2024-05-01)

FTY720 ameliorates GvHD by blocking T lymphocyte migration to target organs and by skin fibrosis inhibition
by: Jaeyoon Ryu, et al.
Published: (2020-06-01)

FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system
by: Felipe V. Pereira, et al.
Published: (2013-07-01)

Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
by: Andrea C. Diaz Diaz, et al.
Published: (2022-07-01)

Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
by: Pere Fontova, et al.
Published: (2021-03-01)

Effect of immunomodulator, fingolimod, on ischemia reperfusion testicular injury in rats: Targeting the role of sphingolipid rheostat (fingolimod on I/R induced testicular injury)
by: Marwa N. Emam, et al.
Published: (2017-06-01)

Ivermectin: Difficulties in resolving pharmacokinetic and pharmacodynamic relationships in onchocerciasis
by: E N Shu, et al.
Published: (2004-01-01)

Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
by: Yangyang Gao, et al.
Published: (2025-01-01)

Pharmacokinetic–Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats
by: Dong-Seok Lee, et al.
Published: (2018-04-01)

Pharmacodynamics and pharmacokinetics of snake antivenom
by: Bhagya Nikapitiya, et al.
Published: (2018-06-01)

Pharmacodynamics and pharmacokinetics of nalbuphine in xylazine‑sedated horses
by: Amal Hammad, et al.
Published: (2023-05-01)

Pharmacodynamics of Five Anthraquinones (Aloe-emodin, Emodin, Rhein, Chysophanol, and Physcion) and Reciprocal Pharmacokinetic Interaction in Rats with Cerebral Ischemia
by: Rong-Rong Li, et al.
Published: (2019-05-01)